Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Q3 FY26: Capex ₹669 Cr
Q3 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Europe sales expected to grow up to 10 times the 2018 level in the next 2-3 years, driven by biosimilars and Abatacept launch; double-digit growth anticipated in all European markets excluding the US. Revenue growth expected to be supported by double-digit growth in all markets except the U.S.
From Dr Reddys Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Europe sales expected to grow up to 10 times the 2018 level in the next 2-3 years, driven by biosimilars and Abatacept launch; double-digit growth anticipated in all European markets excluding the US.
- India business growth sustainable at 15-16%, possibly higher than 19%, supported by innovative products, new acquisitions, and Semaglutide launch.
- Emerging markets like Russia to deliver healthy double-digit sustainable growth through a mix of new and existing products.
- Global generics gross margins expected between 50-55% post-Lenalidomide impact.
- Aurigene CDMO business anticipated to contribute $100+ million in revenue growth in 2-3 years.
2 more points from Dr Reddys Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
Read what Dr Reddys Laboratories Ltd said on margins in the Q3 FY26 call
Free account with your mobile number. We text a one-time code, no password.
Capital Expenditure Plans
- Capex cash outflow for Q3FY26 was ₹669 crores (US$75 million).
- Focus on strategic investments and value-accretive acquisitions and partnerships to create long-term value.
- Ongoing investments in differentiated R&D programs, especially peptides and biosimilars, targeting meaningful commercial opportunities.
- Emphasis on expanding innovation portfolio for India and Emerging markets via in-house development and strategic collaborations.
- Aurigene CDMO opportunity: growing emphasis on exclusive supply of innovative APIs, expected to yield over $100 million revenue growth in next 2-3 years.
2 more points from Dr Reddys Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Dr Reddys Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.5K Cr, net profit ₹221 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Dr Reddys Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Reddys Laboratories Ltd Q3 FY26 results?
Europe sales expected to grow up to 10 times the 2018 level in the next 2-3 years, driven by biosimilars and Abatacept launch; double-digit growth anticipated in all European markets excluding the US. Revenue growth expected to be supported by double-digit growth in all markets except the U.S.
What is Dr Reddys Laboratories Ltd share price analysis?
Dr Reddys Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.1 with a market cap of ₹100,161 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Reddys Laboratories Ltd planning capital expenditure?
Capex cash outflow for Q3FY26 was ₹669 crores (US$75 million).
Keep Dr Reddys Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.